

KOBAYASHI

PHARMACEUTICAL CO., LTD.

Summary Consolidated Financial Results for the Third Quarter Ended December 31, 2008

Note: This document has been prepared as a guide to non-Japanese investors and contains forward-looking statements that are based on managements' estimates, assumptions and projections at the time of publication. A number of factors could cause actual results to differ materially from expectations. This document is a translation of the Japanese language original. All numbers are rounded down to the nearest unit in accordance with standard Japanese practice.

KOBAYASHI PHARMACEUTICAL CO., LTD.

Summary of Consolidated Financial Results for the Third Quarter Ended December 31, 2008

Kobayashi Pharmaceutical, Co., Ltd. (4967)

Exchange Listed:	Osaka and Tokyo, First Section
Principal Office:	Osaka, Japan
Homepage:	http://www.kobayashi.co.jp/english/index.shtml
President and COO:	Yutaka Kobayashi
Contact:	Satoshi Yamane, General Manager Group Corporate Business Headquarters
Telephone:	+81-6222-0084
Expected date of Quarterly Financial Report submission:	February 10, 2009
U.S. (GAAP) accounting standard:	Not adopted for the purposes of these statements.

I. Consolidated Financial Results (April 1, 2008 – December 31, 2008)

(1) Consolidated Operating Results

	Millions of Yen - Except Per Share Data and Percents			
	Third Quarter ended December 31,			
	2008	%	2007	%
Net Sales.....	98,683	—	202,197	(0.1)
Operating Income.....	14,672	—	15,886	(0.9)
Ordinary Income.....	14,127	—	13,815	(1.9)
Net Income	8,782	—	7,901	(6.7)
Net Income per Share (yen).....	214.04		191.06	
Net Income per Share, diluted (yen)	213.96		190.87	

(2) Consolidated Financial Position

	Millions of Yen - Except Per Share Data and Percents	
	Third Quarter ended Dec 31,	FY ended March 31,
	2008	2008
Total Assets	128,504	122,409
Net Assets.....	77,815	77,182
Shareholders' Equity Ratio	60.4%	63.0%
Shareholders' Equity per Share (yen).....	1,896.92	1,863.24
Note: Equity: Third quarter ended Dec 31, 2008		77,674 million yen
Fiscal year ended March 31, 2008		77,103 million yen

KOBAYASHI PHARMACEUTICAL CO., LTD.

II. Dividends

	Fiscal year ended March 31,		
	2008	2009	2009 (forecast)
Annual Dividends per Share			
First quarter (yen)	—	—	—
Interim (yen)	27.00	29.00	—
Third quarter (yen)	—	—	—
End of year (yen)	27.00	—	29.00
Annual Dividends (yen)	54.00	—	58.00

* Revisions to dividend forecast in the quarter: None

III. Outlook for the Fiscal Year Ending March 31, 2009 -- (April 1, 2008 – March 31, 2009)

Consolidated	Millions of Yen - Except Per Share Data and Percents	
	Full Year	%
Net Sales	129,000	(43.6)
Operating Income	15,600	(16.0)
Ordinary Income	15,400	(1.8)
Net Income	8,800	3.5
Net Income per Share (yen)	212.66	

* Revisions to financial forecast in the quarter: None

KOBAYASHI PHARMACEUTICAL CO., LTD.

IV. Additional notes

(1) Transfers of leading subsidiaries during the period (transfers of specified subsidiaries accompanies by changes in the scope of consolidation):

New:	None
Excluded:	No companies

(2) Application of simplified accounting treatment and unique accounting treatment when creating quarterly consolidated financial statements: Yes (please refer to pages 8-9.)

(3) Changes in accounting principles, procedures and methods of presentation relating to the preparation of quarterly consolidated financial statements (Record under Changes to Significant Matters Forming the Basis for the Preparation of Quarterly Consolidated Financial Statements)

(i) Changes accompanying amendments to accounting standards:	Yes
(ii) Changes other than those in (i) above: (please refer to pages 8-9.)	None

(4) Number of outstanding shares (common shares)

(i) Number of shares issued and outstanding at end of period (including treasury stock)

Third Quarter FY2009:	42,525,000	End Fiscal Year 2008:	42,525,000
-----------------------	------------	-----------------------	------------

(ii) Number of shares of treasury stock issued and outstanding at end of period

Third Quarter FY2009:	1,577,329	End Fiscal Year 2008:	1,143,617
-----------------------	-----------	-----------------------	-----------

(iii) Average number of treasury stock during the period

Third Quarter FY2009:	41,029,641	Third Quarter FY2008:	41,356,861
-----------------------	------------	-----------------------	------------

Note:

1. The outlook shown above is prepared based on information available as of the time of writing, and therefore actual results may differ significantly from the projections due to risks and various unknown factors.

The main reason for the decline in sales was the removal of the affiliated company responsible for wholesale operations from the scope of consolidation as of January 1, 2008. In addition, changes in accounting treatment following the application of the Accounting for Inventory Valuation accounting standard impacted both operating income and the ordinary income.

2. Effective from the fiscal period under review, the Company has adopted the Accounting Standard for Quarterly Financial Reporting (ASBJ Statement No.12) and the Guidance on Accounting Standard for Quarterly Financial Reporting (ASBJ Guidance No.14). In addition, the quarterly consolidated financial report is prepared in accordance with the Regulation for Quarterly Consolidated Financial Statements.

KOBAYASHI PHARMACEUTICAL CO., LTD.

V. Business Results and Financial Position

(1) Business Results

Through the third quarter of the current fiscal year, concerns of a slowdown in the Japanese economy intensified for various reasons including jumps in the price of crude oil and raw materials squeezing corporate earnings and household finances. In addition, consumers are becoming more and more defensive in their spending for various reasons, including stagnant growth in employee income and the deterioration in corporate earnings as a result of various factors such as the financial instability stemming from the U.S. subprime mortgage crisis.

In these circumstances, the Kobayashi Group sought to fully cultivate the spirit of the Group philosophy of "Creativity and Innovation", and the development of customer needs by providing products and services to create new markets while offering new value products and services in existing markets.

Kobashou Co., Ltd., which was responsible for wholesale operations, became a wholly-owned subsidiary of Mediceo Paltac Holdings through a stock swap on January 2008. Kobashou's earnings were not included in consolidated figures for the affiliated companies doing wholesale operations starting in the fourth quarter ended in March 2008.

As a result, sales figures for the third quarter ended December 31, 2008, likewise, fell 103,514 million yen (-51.2%) year on year to 98,683 million yen, and operating income fell 1,214 million yen (-7.6%) to 14,672 million yen.

Ordinary income, however, increased 312 million yen (+2.3%) year on year to 14,127 million yen, and net income expanded 880 million yen (+11.1%) year on year to 8,782 million yen.

Operating income fell year on year because of factors that impacted the cost of sales and changes to the accounting treatment of inventory valuations and losses on the valuation and disposal of inventories following the application of the Accounting for Inventory Valuations accounting standard starting this fiscal year.

Consumer Products Operation

Thirteen products were introduced this year, including the OTC medical product Chikunain, which is effective for chronic inflammation of nasal passages, the medicinal cosmetic water Keshimin Eki, which helps prevent blemish and freckles, and the taped sock Aruku Tasuke, which reduces the burden when walking and prevents the feet from getting tired. In addition to firm sales the toilet bowl cleaner Bluelet and the breath refreshener Breath Care, and the sanitary product Sarasaty, all of which are core products, sales of food products, particularly mail order sales, were healthy.

As a result, sales in the third quarter increased 1,336 million yen (+1.5%) year on year to 88,974 million yen.

KOBAYASHI PHARMACEUTICAL CO., LTD.

Operating income in the third quarter fell 1,593 million yen (-9.9%) year on year to 14,509 million yen. This followed factors that impacted the cost of sales, changes in the accounting treatment of inventory valuations and losses on the valuation and disposal of inventories following application of the Accounting for Inventory Valuations accounting standard starting this fiscal year.

Sales by Category

(Millions of Yen)

	Third Quarter ended Dec 31, 2008		Third Quarter ended Dec 31, 2007		Change	
	Amount	%	Amount	%	Amount	%
Pharmaceuticals	16,169	18.2	16,819	19.2	(649)	(3.9)
Oral hygiene products	10,487	11.8	9,922	11.3	565	5.7
Sanitary products	11,967	13.4	11,457	13.1	510	4.5
Deodorizing air fresheners	25,540	28.7	25,688	29.3	(147)	(0.6)
Household sundries	3,440	3.9	3,610	4.1	(170)	(4.7)
Food products	9,856	11.1	9,249	10.6	607	6.6
Body warmers	11,512	12.9	10,890	12.4	621	5.7
Total	88,974	100.0	87,637	100.0	1,336	1.5

Note: Sales include internal sales or transfers between segments, which amounted to 26,297 million yen for the previous third quarter consolidated cumulative period and 19 million yen for the current period.

Medical Devices Operation

Within the medical devices operations, efforts were made to raise brand awareness and expand the company's market share in the fields of orthopedic and operating room related products, the domestic market for which is expected to grow.

As a result, sales in the third quarter rose 515 million yen (+6.6%) year on year to 8,352 million yen. The Group also recorded an operating loss of 260 million yen in the third quarter, compared to an operating loss of 317 million yen a year ago, since aggressive investments were continuously made in the eVent Medical Inc.'s artificial ventilator business.

Sales by Category

(Millions of Yen)

	Third Quarter ended Dec 31, 2008		Third Quarter ended Dec 31, 2007		Change	
	Amount	%	Amount	%	Amount	%
Kobayashi Medical Company	6,961	83.4	6,430	82.1	530	8.3
eVent Medical Ltd.	518	6.2	605	10.2	(86)	(14.3)
Others	872	10.4	799	7.7	72	9.0
Total	8,352	100.0	7,836	100.0	515	6.6

Note: Sales excludes internal sales or transfers between segments.

KOBAYASHI PHARMACEUTICAL CO., LTD.

Other Operations

Other Operations (transportation, sales promotion, market research, etc.) are conducted on a financially independent basis by Kobayashi Pharmaceutical's subsidiaries in support of the Company's two principal businesses and to contribute to the profits of those businesses. The Group reviewed the transfer values of the materials and services these operations provide.

Therefore, sales in the third quarter fell 247 million yen (-4.0%) year on year to 5,957 million yen, but operating income rose 96 million yen (+28.8%) year on year to 430 million yen. However, sales include internal sales or transfers between segments, which totaled 4,799 million yen during the third quarter a year ago and 4,580 million for current quarter.

(2) Consolidated Financial Position

Current assets rose year on year to 74,803 million yen as a result of growth in cash and time deposits, and growth in trade notes and accounts receivable, and a decline in securities.

Fixed assets fell year on year slightly to 53,700 million yen since there was an increase in assets covered by lease accounting, a decrease in goodwill, and a decline in investments in securities.

Therefore, total assets equaled 128,504 million yen.

Liabilities rose year on year to 50,689 million yen for various reasons including an increase in trade notes and accounts payable, an increase in accrued expenses, and an increase in lease liabilities due to the application of lease accounting.

Net assets grew year on year to 77,815 million yen as the earned surplus rose, net unrealized holdings on securities fell, and the foreign currency translation adjustments shrank.

(3) Forecasts for Fiscal Year Ending March 31, 2009

Sales for the third quarter were slightly below initial forecasts, but income generally came in as expected since sales of existing products with high profit margins were firm and costs were cut.

Both the Japanese and overseas economies are expected to continue to contract, and market conditions are projected to become even harsher. At the present time, earnings, however, are not expected to change substantially since various efforts are being made, including expanding sales of existing products, introducing new high added value products, and reducing costs. Therefore, consolidated earnings forecasts announced on May 8, 2008, have been left unchanged.

KOBAYASHI PHARMACEUTICAL CO., LTD.

(4) Other

(1) Transfers of leading subsidiaries during the fiscal period (transfers of specified subsidiaries accompanied by changes in the scope of consolidation): None

(2) Application of simplified accounting procedures and specific accounting procedures in preparing quarterly consolidated financial statements

Simplified accounting treatment

i) Method for estimating the amount of uncollectable general account receivables

The uncollectable amount is estimated using the actual bad debt ratio calculated at the end of the previous fiscal year since there were no substantial changes in figures for items such as the actual bad debt ratio at the end of the third quarter of the current fiscal year compared to that at the end of the previous fiscal year.

ii) Inventory valuation method

Inventory at the end of the third quarter of the current fiscal year was calculated using a reasonable method without actually taking inventory. Concerning the write-down of the book value of inventories, only for those items whose drop in profitability was apparent, an estimate of net sale value was made and book values were written down.

iii) Method for calculating items such as income tax

The amount of payable income tax was calculated only taking into account material changes in items and deductions. The probability of recovering deferred tax assets was determined using tax planning and forecasts employed for the previous fiscal year since there were no notable temporary deviations or changes in factors such as business conditions since the end of the previous fiscal year.

(3) Changes in accounting principles, procedures and methods of presentation relating to the preparation of quarterly consolidated financial statements

Changes in accounting principles

i) Application of Accounting Standard for Quarterly Financial Reporting

Effective from the fiscal period under review, the Company has adopted the Accounting Standard for Quarterly Financial Reporting (ASBJ Statement No.12) and the Guidance on Accounting Standards for Quarterly Financial Reporting (ASBJ Guidance No.14). In addition, the quarterly consolidated financial report is prepared in accordance with the Regulation for Quarterly Consolidated Financial Statements.

KOBAYASHI PHARMACEUTICAL CO., LTD.

ii) Material changes in the criteria and method for valuing assets

Inventories

Inventories held for the purpose of sales, which have traditionally and mainly been accounted for using a cost method based on the period average, will mainly be accounted for using the cost method based on the period average (a method for reducing the balance sheet book value due to a decline in profitability) following the application of the Accounting for Inventory Valuation accounting standard (ASBJ Statement No.9; July 5, 2006).

This had only a minor impact on income and segment information.

Following application of this standards, the loss on valuation and disposal of inventories, which have traditionally been recorded as non-operating expenses and extraordinary losses, are included as cost of sales.

While this reduced operating income by 1,398 million yen and ordinary income by 307 million yen, it had no effect on net income before provision for income taxes. The effect on segment information is discussed in the relevant location.

iii) Application of items such as accounting standards related to leases

Finance leases in which ownership is not transferred have traditionally been accounted for in a manner equivalent to that for leases. Accounting Standard for Lease Transactions (ASBJ Statement No.13; June 17, 1993 (Business Accounting Council - No. 1 Subcommittee); revised March 30, 2007) and Implementation Guidelines for Accounting Standard for Lease Transactions (ASBJ Guidance No.16; January 18, 1994 (Japanese Institute of Certified Public Accountants - Accounting System Committee); revised March 30, 2007) can be applied to the quarterly financial statements for the consolidated fiscal year starting on April 1, 2008, or later. These accounting standards have been applied starting with the first quarter of the current fiscal year, and finance leases are accounted for as normal sales.

In addition, finance leases assets without transfer of ownership are amortized by the straight-line method at rates based on lease term, without any residual value.

This had only a minor impact on income and segment information.

(4) Supplementary Data

As of the first quarter of the current fiscal year, the useful life of equipment at the Company and its Japanese consolidated subsidiaries was reviewed and changed for some equipment following revisions to the Corporate Tax Law. This had only a minor impact on income and segment information.

KOBAYASHI PHARMACEUTICAL CO., LTD.

VI. Consolidated Financial Statements

(1) Consolidated Balance Sheets

	Millions of Yen	
	As of Dec 31,	As of March 31,
	2008	2008
Assets	Note	Note
Current assets:		
Cash and time deposits.....	20,042	17,164
Trade notes and accounts receivable	35,267	26,231
Securities.....	1,002	5,799
Finished goods and products.....	11,019	9,934
Work in progress.....	591	630
Raw material and supply	2,090	1,788
Other current assets	4,841	4,524
Allowance for doubtful accounts	(51)	(3)
Total Current Assets	74,803	66,069
Fixed Assets:		
Tangible Fixed Assets:		
Buildings and structures (Net).....	7,146	7,399
Machinery and equipment (Net).....	1,513	1,471
Land	5,244	5,244
Other (Net)	3,320	1,119
Total Fixed Assets	17,224	15,235
Intangible Assets:		
Goodwill	8,907	10,675
Other	2,340	2,127
Total Intangible Assets.....	11,247	12,803
Investments and Other Assets:		
Investments in securities.....	19,703	24,677
Other Assets.....	5,720	3,697
Allowance for investment liability loss.....	(109)	—
Allowance for doubtful accounts	(86)	(73)
Total Investments and Other Assets	25,228	28,301
Total Fixed Assets	53,700	56,340
Total Assets	128,504	122,409

KOBAYASHI PHARMACEUTICAL CO., LTD.

	Millions of Yen	
	As of Dec 31,	As of March 31,
	2008	2008
Liabilities		
Current Liabilities:		
Trade notes and accounts payable.....	17,472	15,317
Short-term loans payable.....	551	726
Accrued expenses	13,316	12,995
Accrued income taxes.....	3,667	3,690
Reserve for returned goods unsold	1,538	1,245
Allowance for bonus payable.....	928	1,755
Other current liabilities	4,072	2,210
Total Current Liabilities	41,547	37,940
Fixed Liabilities:		
Long term loans payable.....	207	—
Allowance for retirement benefits	4,588	4,486
Provision for allowances for directors and corporate auditors	1,539	1,451
Other fixed liabilities.....	2,806	1,348
Total Fixed Liabilities	9,141	7,286
Total Liabilities	50,689	45,226
Net Assets		
Shareholders' Equity		
Common stock.....	3,450	3,450
Capital surplus	4,219	4,213
Earned surplus	78,606	72,129
Cost of treasury stock.....	(4,705)	(3,230)
Total Shareholders' Equity	81,570	76,562
Appraisal and Translation Differences		
Net unrealized holdings on securities	(1,332)	1,571
Gain/loss on deferred hedge.....	(1,125)	(690)
Foreign currency translation adjustment.....	(1,438)	(339)
Total Appraisal and Translation Differences	(3,896)	540
Stock Acquisition Rights	126	63
Minority Interests.....	14	16
Net Assets	77,815	77,182
Total Liabilities and Net Assets.....	128,504	122,409

KOBAYASHI PHARMACEUTICAL CO., LTD.

(2) Consolidated Statements of Income

	Millions of Yen
	April 1 to Dec 31, 2008
Net Sales	98,683
Cost of sales	44,547
Gross income.....	54,136
Selling, general, and administrative expenses	39,463
Operating Income	14,672
Non-Operating Income:	
Interest income	116
Dividend income	236
Royalty income	413
Other.....	169
Non-Operating Income	935
Non-Operating Expenses:	
Interest expenses.....	114
Sales discount.....	952
Investment loss on equity method	60
Loss on translation.....	235
Other.....	117
Non-Operating Expenses	1,481
Ordinary Income	14,127
Extraordinary Gain and Loss:	
Gain on sales of goodwill	1,102
Gain on sales of investments in securities	382
Other.....	76
Extraordinary Gains	1,560
Non-recurring expenses accompanying the collection of products	76
Loss on sales and disposal of fixed assets	67
Provision for allowance for investment loss.....	109
Other.....	28
Extraordinary Losses	282
Income Before Provision for Income Taxes	15,405
Corporate Income, Local and Business Taxes.....	6,644
Adjustments to Income Taxes	(19)
Total Income Taxes, etc.	6,625
Minority loss in Net Income of Consolidated Subsidiaries.....	(1)
Net Income	8,782

KOBAYASHI PHARMACEUTICAL CO., LTD.

Effective from the fiscal period under review, the Company has adopted the Accounting Standard for Quarterly Financial Reporting (ASBJ Statement No.12) and the Guidance on Accounting Standard for Quarterly Financial Reporting (ASBJ Guidance No.14). In addition, the quarterly consolidated financial report is prepared in accordance with the Regulation for Quarterly Consolidated Financial Statements.

(3) Notes regarding continuing concern

None

(4) Segment Information

Segment Information by Business Category

Current Consolidated Third Quarter - (April 1 - December 31, 2008)

(Millions of Yen)

	Consumer Products Operation	Medical Devices Operation	Other	Total	Elimination / corporate	Consolidated
Sales						
I. Sales to third parties	88,954	8,352	1,376	98,683	—	98,683
II. Inter-group sales and transfers	19	—	4,580	4,599	(4,599)	—
Total	88,974	8,352	5,957	103,283	(4,599)	98,683
Operating income / losses	14,509	(260)	430	14,679	(6)	14,672

1. Classification of Business

Businesses segments are classified following the product line, and the markets in which the products are distributed.

2. Main Products by Business Segment

Segment	Main Products
Consumer products operation	Pharmaceuticals, oral hygiene products, sanitary products, deodorizing air fresheners, household sundries, food products, and body warmers
Medical devices operation	Medical devices
Others	Transport, synthetic resin products manufacturing, insurance agency business, real estate management, advertising plan and creation

3. Changes in Accounting Principles

(Accounting for Inventory Valuation accounting standard)

As noted in 1. (1) "Important Matters in the Preparation of Consolidated Financial Statements", the Accounting for Inventory Valuation accounting standard (ASBJ Statement No. 9; July 5, 2006), was applied starting in the consolidated first quarter. This resulted in operating income for the consumer products operation declining 1,381 million yen, operating income for the medical device operation declining 13 million yen, and operating income for others declining 2 million yen, as compared with the application of the previous method.

KOBAYASHI PHARMACEUTICAL CO., LTD.

4. Omission of some business in segment information

As for wholesale operations, which have traditionally been an important segment, the segment was omitted from segment information starting from the first quarter of the current fiscal year since Kobashou Co., Ltd., which handled wholesale operations, was turned into a wholly-owned subsidiary of Mediceo Paltac Holdings, through a stock swap in the fourth quarter of the fiscal year ended March 31, 2008, and excluded from the scope of consolidation.

Segment Information by Area

Since sales in Japan account for more than 90% of total sales for all segments, segment information by region has been omitted.

Overseas Sales

In this term, overseas sales are omitted from this report because this item accounted for less than 10% of consolidated sales.

(5) Significant change in shareholders' equity

None

KOBAYASHI PHARMACEUTICAL CO., LTD.

VII. Reference

(1) Consolidated Statements of Income (Summary)

Previous Consolidated Third Quarter - (April 1 - December 31, 2007)

	(Millions of Yen) Third Quarter Ended December 31, 2007		%
Net Sales	202,197		100.0
Cost of sales	135,847		67.2
Gross income.....	66,349		32.8
Selling, general, and administrative expense	50,462		25.0
Operating Income	15,886		7.8
Non-Operating Income	1,214		0.6
Royalty income.....	329		
Interest income	117		
Other.....	768		
Non-Operating Expenses	3,286		1.6
Losses on disposal of inventory evaluation	2,015		
Sales discount.....	983		
Other.....	287		
Ordinary Income	13,815		6.8
Extraordinary Gains	1,543		0.8
Gain on sales of goodwill	1,277		
Gain on sales of fixed assets.....	1		
Other extraordinary gains	264		
Extraordinary Losses	1,360		0.7
Losses on disposal of fixed assets	68		
Losses on variation of disposal of inventory	617		
Provision for allowance for investment loss.....	119		
Impairment loss.....	15		
Other extraordinary losses	539		
Income Before Provision for Income Taxes	13,998		6.9
Corporate Income, Local and Business Taxes	5,995		
Adjustments to Income Taxes	102		
Minority loss in Net Income of Consolidated Subsidiaries	(0)		(0.0)
Net Income	7,901		3.9

KOBAYASHI PHARMACEUTICAL CO., LTD.

(2) Segment Information

1) Segment Information by Business Category

Previous Consolidated Third Quarter (April 1 – December 31, 2007)

(Millions of Yen)

Sales and operating income	Consumer Products Operation	Wholesale Operation	Medical Devices Operation	Other Operations		Elimination/ corporate	Consolidated
I. Sales to third parties	61,340	131,615	7,836	1,405	202,197	—	202,197
II. Inter-group sales and transfers	26,297	359	—	4,799	31,456	(31,456)	—
Total net sales	87,637	131,975	7,836	6,204	233,653	(31,456)	202,197
Operating expense	71,535	131,879	8,154	5,869	217,438	(31,127)	186,310
Operating income / losses	16,102	96	(317)	334	16,215	(328)	15,886

Method of business classification:

Businesses segments are classified following the product line, and the markets in which the products are distributed.

Main products of each business operation:

Consumer Products Operations --- pharmaceuticals, oral hygiene products, sanitary products, deodorizing air fresheners, household sundries, food products, and body warmers.

Wholesale Operation --- household pharmaceuticals, household sundries and foods

Medical Devices Operation --- medical devices

Other Operation --- transport, synthetic resin products manufacturing, insurance agency business, real estate management, advertising plan and creation.

2) Segment Information by Area

Since sales in Japan account for more than 90% of total sales for all segments, segment information by region has been omitted.

3) Overseas Sales

In this term, overseas sales are omitted from this report because this item accounted for less than 10% of consolidated sales.